OBJECTIVES: To evaluate the impact on CD4 cell count and HIV-1 DNA level in peripheral blood mononuclear cells (PBMC) of long-term highly active antiretroviral therapy (HAART) in the setting of maximal success, i.e., constant plasma HIV-1 RNA load suppression. DESIGN: Retrospective analysis of patients selected for a constantly undetectable plasma HIV-1 RNA load since HAART initiation. METHODS: HIV-1 DNA was measured in PBMC using a real-time polymerase chain reaction assay. Loess estimates and regression analysis were used for modelling the variations of the CD4 cell count and HIV DNA level over time. RESULTS: The study included 41 patients chronically infected with HIV-1 who had been taking HAART for a median duration of 60.4 months and had an undetectable plasma HIV RNA load ever since the first 6 months of HAART; 25 were tested for HIV-1 DNA. The mean CD4 cell count increase was high during the first 18 months on therapy (168 x 10 cells/l per year), much lower afterwards (38 x 10 cells/l per year), independently of the baseline CD4 cell count. Most of the patients (73.2%) reached a CD4 cell count constantly > or = 400 x 10/l during follow-up. HIV-1 DNA showed a mean decrease of 0.48 log10 copies/10 PBMC during the first year, of 0.18 log10 copies/10 PBMC per year during the 2nd and 3rd years, but no significant decrease afterwards. CONCLUSIONS: These results question the benefit of very long-term maintenance of HAART in terms of CD4 gain and HIV-1 DNA reduction.
OBJECTIVES: To evaluate the impact on CD4 cell count and HIV-1 DNA level in peripheral blood mononuclear cells (PBMC) of long-term highly active antiretroviral therapy (HAART) in the setting of maximal success, i.e., constant plasma HIV-1 RNA load suppression. DESIGN: Retrospective analysis of patients selected for a constantly undetectable plasma HIV-1 RNA load since HAART initiation. METHODS:HIV-1 DNA was measured in PBMC using a real-time polymerase chain reaction assay. Loess estimates and regression analysis were used for modelling the variations of the CD4 cell count and HIV DNA level over time. RESULTS: The study included 41 patients chronically infected with HIV-1 who had been taking HAART for a median duration of 60.4 months and had an undetectable plasma HIV RNA load ever since the first 6 months of HAART; 25 were tested for HIV-1 DNA. The mean CD4 cell count increase was high during the first 18 months on therapy (168 x 10 cells/l per year), much lower afterwards (38 x 10 cells/l per year), independently of the baseline CD4 cell count. Most of the patients (73.2%) reached a CD4 cell count constantly > or = 400 x 10/l during follow-up. HIV-1 DNA showed a mean decrease of 0.48 log10 copies/10 PBMC during the first year, of 0.18 log10 copies/10 PBMC per year during the 2nd and 3rd years, but no significant decrease afterwards. CONCLUSIONS: These results question the benefit of very long-term maintenance of HAART in terms of CD4 gain and HIV-1 DNA reduction.
Authors: Francesco Marras; Anna Casabianca; Federica Bozzano; Maria Libera Ascierto; Chiara Orlandi; Antonio Di Biagio; Emanuele Pontali; Chiara Dentone; Giancarlo Orofino; Laura Nicolini; Lucia Taramasso; Mauro Magnani; Francesco M Marincola; Ena Wang; Lorenzo Moretta; Andrea De Maria Journal: J Virol Date: 2017-11-14 Impact factor: 5.103
Authors: S T Wright; K Petoumenos; M Boyd; A Carr; S Downing; C C O'Connor; M Grotowski; M G Law Journal: HIV Med Date: 2012-10-04 Impact factor: 3.180
Authors: Benoît Vingert; Santiago Perez-Patrigeon; Patricia Jeannin; Olivier Lambotte; Faroudy Boufassa; Fabrice Lemaître; William W Kwok; Ioannis Theodorou; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti Journal: PLoS Pathog Date: 2010-02-26 Impact factor: 6.823
Authors: Victoria L Demetriou; David A M C van de Vijver; Ioanna Kousiappa; Claudia Balotta; Bonaventura Clotet; Zehava Grossman; Louise B Jørgensen; Snjezana Z Lepej; Itzchak Levy; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Francois Roman; Lidia Ruiz; Jean-Claude Schmidt; Anne-Mieke Vandamme; Kristel Van Laethem; Jurgen Vercauteren; Leondios G Kostrikis Journal: PLoS One Date: 2010-06-08 Impact factor: 3.240